Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Apr

Today In Oncology

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL

Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers

Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer

FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings